Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports

Annals of Oncology

Volumn 8, Issue 10, 1997, Pages 1049-1051

  Wasserman, E ^a,e   Myara, A ^b   Lokiec, F ^c   Goldwasser, F ^a   Trivin, F ^b   Mahjoubi, M ^d   Misset, J L ^a   Cvitkovic, E ^a  

^a FSMSIT   (France)

^b SAINT JOSEPH HOSPITAL   (France)

^c CENTRE RENÉ HUGUENIN   (France)

^d SANOFI   (France)

^e HÔPITAL PAUL BROUSSE   (France)

Author keywords

Bilirubin; CPT 11; Gilbert's syndrome; Glucuronidation; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BILIRUBIN; DRUG METABOLITE; FLUOROURACIL; GLUCURONIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; OXALIPLATIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; COLON CANCER; DIARRHEA; FEMALE; GILBERT DISEASE; GLUCURONIDATION; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; PRIORITY JOURNAL;

BILIRUBIN; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; GILBERT DISEASE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS;

EID: 0030716924     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008261821434     Document Type: Article

References (14)

1. O'Reilly S, Rowinsky E. The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996. Crit Rev Oncol/Hematol 1996; 24: 47-70.
2. Gupta E, Wang X, Ramirez J, Ratain M. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol 1997; 39: 440-4.
3. Gupta E, Lestingi T, Mick R et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54: 3723-5.
4. Iyer L, King C, Tephly T and Ratain MJ. UGT isoform 1.1 (UGT* 1.1) glucuronidates SN-38. the active metabolite of irinotecan. Proc Am Soc Clin Oncol 1997; 16: 707 (Abstr).
5. Bosma P, Chowdhury J, Bakker C et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase I in Gilbert's syndrome. N Engl J Med 1995; 333: 1171-5.
6. Morais SF, Wells PG. Enhanced acetaminophen toxicity in rats with bilirubin glucuronyl transferase deficiency. Hepatology 1989; 10: 163-7.
7. Cvitkovic E, Wasserman E, Goldwasser F et al. Preliminary report on an Oxaliplatin (L-OHP)/CPT-11 phase I trial in gastrointestinal malignancies: an active combination. Proc Am Soc Clin Oncol 1997; 16:711 (Abstr).
8. Muraca M, Blanckaert N. Liquid-chromatographic assay and identification of mono- and diester conjugates of bilirubin in normal serum. Clin Chem 1983; 29: 1767-71
9. Feveri J, Blanckaert N. What can we learn from analysis of serum bilirubin'? J Hepatol 1986; 2: 113-21.
10. Canal P, Gay C, Dezeuze A et al. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 1996; 14: 2688-95.
11. Wasserman E, Myara A, Paumier D et al. Baseline bilirubin and its transient early increase predicts likelihood of severe neutropenia and diarrhea in CPT-11 based chemotherapy. Proc Am Soc Clin Oncol 1997; 16: 767 (Abstr).
12. O'Dwyer PJ, Johnson SW, Hamilton TC. Cisplatin and ils analogues. In DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, Vol 1, 5th ed. Philadelphia: Lippincott 1997; 426.
13. Brienza S, Vignoud J, Itzhaki M, Krikorian A. Oxaliplatin (L-OHP): Global safety in 682 patients. Proc Am Soc Clin Oncol 1995; A513.
14. Massari C, Brienza S, Rotarski M et al. Oxaliplatin, Transplatin* (Tp® ) comparative pharmacokinetics in normal and impaired renal function patients. Proc Am Assoc Cancer Res 1994; A1445.